Good afternoon :)
$
₹
Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SNDX

NASDAQ
Asset Logo

Syndax Pharmaceuticals Inc

SNDX

NASDAQ
$9.531.71% (+0.16)
$
₹
$9.531.71% (+0.16)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $940.8M the stock is ranked 2778

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

84.74
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.37
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-72.32%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
12 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+290.7%

Earnings Growth

+41.96%

Rev. Growth

+83.56%

See Detailed Forecast

Company Profile

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 290.70% growth, versus a trailing 3-year CAGR of -12.82%.

2026
Current$9.54Baseline
Analyst Target - 1 year
Target$37.27+290.7%

All values in $

202220232024202520262027$16.69$24.79$32.89Target+290.7%
2026
Current$9.54Baseline
Analyst Target - 1 year
Target$37.27+290.7%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$172.35Baseline
Forecast for Dec 2026
High$332.88+93.14%
Average$316.36+83.56%
Low$308.83+79.19%

All values in $ Million

202120222023202420252026139.70126.57023.68172.35Low+79.19%Average+83.56%High+93.14%
2025
Current$172.35Baseline
Forecast for Dec 2026
High$332.88+93.14%
Average$316.36+83.56%
Low$308.83+79.19%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.29Baseline
Forecast for Dec 2026
High$-1.35+58.97%
Average$-1.91+41.96%
Low$-2.24+31.91%

All values in $

2021202220232024202520260.43-2.45-2.96-3.73-3.29Low+31.91%Average+41.96%High+58.97%
2025
Current$-3.29Baseline
Forecast for Dec 2026
High$-1.35+58.97%
Average$-1.91+41.96%
Low$-2.24+31.91%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

68.4
-68
64.8
-42.6
72.7
-49.3
83.2
-49.4
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue3.512.57.6820.0437.9545.8768.4864.8672.7883.29
Net Income-68.06-84.12-94.16-84.84-71.84-60.71-68.01-42.67-49.36-49.43
Net Profit Margin-1944.65%-673.00%-1226.15%-423.34%-189.28%-132.36%-99.31%-65.78%-67.81%-59.34%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Syndax Pharmaceuticals Inc -84.740
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SNDX with any stock or ETF
Compare SNDX with any stock or ETF
Comparing from
SNDX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Syndax Pharmaceuticals Inc (SNDX) share price today is $9.53 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $9.76 and a day low of $9.25.

  2. Syndax Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol SNDX.

  3. Syndax Pharmaceuticals Inc's market capitalization is $940.79M as of November 7, 2026 at 2:29 AM IST.

  4. Syndax Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Syndax Pharmaceuticals Inc's price-to-book (P/B) ratio is 84.74 as of November 6, 2026.

  6. Yes, You can buy Syndax Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Syndax Pharmaceuticals Inc shares in three steps: 1. Search Syndax Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Syndax Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Syndax Pharmaceuticals Inc (SNDX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.0492 shares at the current price of $9.53.

Loading...